SCHEMBL24257568

SCHEMBL24257568

CCOC(=O)CNC(=O)c1ncc(-c2cccc(Cl)c2)c(C)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 10/20 0.58
VEGFA P15692 7/20 0.58
FLT1 P17948 7/20 0.58
EGLN3 Q9H6Z9 5/20 0.58
TET3 O43151 1/20 0.50
BBOX1 O75936 1/20 0.50
ASPH Q12797 1/20 0.50
TET2 Q6N021 1/20 0.50
KDM8 Q8N371 1/20 0.50
OGFOD1 Q8N543 1/20 0.50
TET1 Q8NFU7 1/20 0.50
HIF1AN Q9NWT6 1/20 0.50
MAPT P10636 1/20 0.47
DYRK3 O43781 1/20 0.43
DYRK1A Q13627 1/20 0.43
DYRK2 Q92630 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
PPID Q08752 1/20 0.41
HTT P42858 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257693 0.88 EGLN1 (0.51) EGLN1VEGFAFLT1EGLN3PPID
SCHEMBL24257790 0.88 EGLN1 (0.53) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257633 0.87 EGLN1 (0.65) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL30452969 0.87 GAA (0.51) EGLN1VEGFAFLT1EGLN3PPID
SCHEMBL24257793 0.87 GAA (0.51) EGLN1VEGFAFLT1EGLN3PPID
SCHEMBL30452626 0.87 EGLN1 (0.52) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257642 0.87 EGLN1 (0.52) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257697 0.85 EGLN1 (0.50) EGLN1BBOX1ASPHKDM8
SCHEMBL24257545 0.84 ALDH1A1 (0.46) EGLN1VEGFAFLT1EGLN3PPID
SCHEMBL30546822 0.84 ALDH1A1 (0.46) EGLN1VEGFAFLT1EGLN3PPID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 EGLN1 19/4885VEGFA 1862/4885FLT1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.